We suggest that inhibition of APOL1 translocation into the lumen of the ER may serve as a potential therapeutic target that might mitigate APOL1 toxicity and the risk for kidney disease in individuals with the two APOL1 risk allele genotype. This evidence concerns the gene APOL1 and kidney disorder.